



## PRESS RELEASE

Stockholm, September 13, 2007

Johan Löf, Erik Hedlund, Anders Brahme, Carl Filip Bergendal, Anders Liander and Bengt Lind ("the Principal Owners") divested 561,174 B shares in RaySearch Laboratories AB (publ) ("RaySearch"). This corresponds to 1.1 % of the votes and 4.8 % of the capital in RaySearch. Accordingly, as of September 13, 2007 the Principal Owners hold shares corresponding to 84.8 % of the votes and 41.1 % of the capital in RaySearch.

The Principal Owners divested shares at the same time as employees, who slightly more than two years ago, acquired shares in RaySearch through an option program, sold 98,905 (of which Anders Liander 10,079) of these shares in a coordinated procedure.

The total number of shares which were sold, were 650,000.

Johan Löf sold 277,797 shares, Erik Hedlund 69,730 shares, Anders Brahme 61,857 shares, Carl Filip Bergendal 47,237 shares, Anders Liander 47,237 plus 10,079 which totals 57,316 shares and Bengt Lind 47,237 shares, all of which were series B. Refer to the table below regarding the Principal Owners' shareholdings after the sales.

A key purpose of the Principal Owners' sales was to continue to improve the liquidity in the RaySearch B share, which is listed on the Nordic Exchange in the Mid Cap segment and classified within the Health Care sector. The Principal Owners will remain as long-term majority owners in RaySearch.

Johan Löf, Erik Hedlund, Anders Brahme and Carl Filip Bergendal are bound to retain, through their series A shares, a voting majority in RaySearch through 2012 in accordance with agreements with two of the company's cooperation partners. The Principal Owners have agreed not to sell additional shares in RaySearch within the next six months.

The purchasers of the shares were a number of international and Swedish institutional investors.

The holdings of the Principal Owners before the sales are shown below.

	A shares	B shares	Votes in %	Capital in %
Johan Löf	2,081,028	558,928	43.3	23.1
Erik Hedlund	522,363	145,963	10.9	5.8
Anders Brahme	463,387	128,657	9.7	5.2
Carl Filip Bergendal	353,859	98,877	7.4	4.0

Anders Liander	353,859	119,035	7.4	4.1
Bengt Lind	353,859	73,877	7.3	3.7
Total	4,128,355	1,125,337	85.9	45.9

The holdings of the Principal Owners after the sales are shown below.

	A shares	B shares	Votes in %	Capital in %
Johan Löf	2,081,028	281,131	42,7	20.7
Erik Hedlund	522,363	76,233	10.7	5.2
Anders Brahme	463,387	66,800	9.5	4.6
Carl Filip Bergendal	353,859	51,640	7.3	3.6
Anders Liander	353,859	61,719	7.3	3.6
Bengt Lind	353,859	26,640	7.2	3.3
Total	4,128,355	564,163	84.8	41.1

Handelsbanken was the financial advisor to RaySearch and the Principal Owners.

**For further information:**

Johan Löf

President and CEO, RaySearch Laboratories AB

Telephone: +46 (0)8-545 061 30

[johan.lof@raysearchlabs.com](mailto:johan.lof@raysearchlabs.com)

**About RaySearch**

RaySearch's business concept is to provide innovative software to radiation therapy clinics for more effective radiation treatment of cancer. RaySearch, a spin-off from Karolinska Institutet, was formed in 2000. Through a licensing agreement with Philips, the company's first product, p-RayOptimizer, has to date been sold to over 1,000 hospitals internationally and more than 100,000 patients have received improved radiation therapy. A licensing agreement was signed with Nucletron at the beginning of 2004 and deliveries of the first product based on this partnership, n-RayOptimizer, began in April 2005. In February 2006 an agreement was signed with Scanditronix-Wellhöfer regarding development of products for improved quality assurance of IMRT. In October 2006, RaySearch signed an agreement with Philips covering the development of products in adaptive radiation therapy. In November 2006 RaySearch signed a development and license agreement with Nucletron regarding treatment planning for proton therapy in cancer treatment. In May 2007 RaySearch signed a long-term collaboration agreement with Varian Medical Systems to develop advanced radiotherapy treatment planning. An agreement was signed with TomoTherapy in August 2007 regarding two products aimed to simplify the treatment process for clinics with both conventional linacs and TomoTherapy systems.

RaySearch is listed on the Nordic List in the Mid Cap segment of the Health Care sector. RaySearch is based in Stockholm.

RaySearch Laboratories AB (publ)

Sveavägen 25

SE-111 34 Stockholm

Telephone: +46 (0)8-545 061 30

Company website: [www.raysearchlabs.com](http://www.raysearchlabs.com)